Professor Marc-Eric Halatsch
Vice chair of neurosurgery at the University of Ulm in Germany, Marc specializes in spinal and oncological neurosurgery. Working with some of the most deadly tumors known to medicine, Marc considers it an ethical responsibility of the medical community to think outside the box for patients facing terminal prognosis. His central involvement in innovative efforts such as CUSP9 and MAP-ND illustrate his patient sensitive approach to his practice.
Gauthier Bouche, MD
Medical Director, Anticancer Fund
Gauthier holds a MD from the University of Poitiers, France and a MPH from the University of Bordeaux, France. After a few years as assistant professor in public health, epidemiology and clinical research at the University of Poitiers, his main focus is now on clinical research in cancer. He serves as the Medical Director of the Anticancer Fund.
Lydie Meheus, PhD
Managing Director, Anticancer Fund
Lydie Meheus, PhD, is Managing Director of the Anticancer Fund (ACF) and Executive Director of Reliable Cancer Therapies (RCT). She holds a PhD in Protein Biochemistry. In 1987, Meheus began work as a senior researcher at Innogenetics, Belgium, where she subsequently held numerous positions. When Innogenetics incorporated its therapeutic activities into a new company, GENimmune, in 2007, she became Vice President for R&D. She began working at RCT in 2009 and ACF in 2013.
Scientist, Patient Advocate
Pan Pantziarka, based in London, is a scientist working at Anticancer Fund. He is the joint coordinator of the Re-purposing Drugs in Oncology project that the ACF has founded in partnership with the US not-for-profit organization Global Cures. In addition to looking at re-using existing non-cancer drugs as new sources of cancer treatments, the project also looks at the social and institutional factors influencing cancer policy. By training Pan is a data scientist and author but has switched fields to oncology. He has previously published in the area of cancer pre-disposition syndromes and is also chairman of the George Pantziarka TP53 Trust.
Richard E. Kast, MD
Clinical Psychiatrist, Neuro-oncology Researcher
After graduation from the University of Copenhagen, Faculty of Medicine and completion of a medical internship year at the State University of New York at Buffalo Hospitals Richard worked as a General Medical Officer with the US Indian Health Service and various other postings before returning for a psychiatry residency, graduating from the University of Vermont, School of Medicine, Department of Psychiatry. Richard has been in general psychiatry practice since then. In over 100 peer-reviewed publications Richard has explored a wide variety of subjects, mainly on inflammation and drug repurposing in cancer. The last two dozen publications were devoted to growth stimulation mechanisms in glioblastoma and repurposed current drugs to inhibit them.
Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3)
To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria:
a) were pharmacologically well characterized,
b) had low likelihood of adding to patient side effect burden,
c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and
d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth.
We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol.
The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are: aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin to be added to continuous low dose temozolomide.
We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma’s compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed.